Clinical Trial Update: AEG35156 in Combination With High-dose Cytarabine and Idarubicin in AML Following Failure of a Single Standard Dose Cytarabine Based Frontline Induction Regimen [Phase 2]

View source ↗

Summary

Phase 2 trial of AEG35156 with high-dose cytarabine and idarubicin in acute myeloid leukemia was terminated after failure of frontline cytarabine-based inductio…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• AEG35156 (XIAP antisense oligonucleotide)
• CYTARABINE (CYTARABINE)
• Idarubicin (idarubicin)

Snippet

Sponsor: Aegera Therapeutics | Conditions: Leukemia | Phase 2 | Status: TERMINATED